OUTLOOK THERAPEUTICS, INC. SHAREHOLDER ALERT: Bernstein Liebhard LLP Announces that a Securities Class Action Lawsuit Has Been Filed Against Outlook Therapeutics, Inc. (NASDAQ: OTLK)


NEW YORK, Nov. 07, 2023 (GLOBE NEWSWIRE) -- Bernstein Liebhard LLP:

  • Do you, or did you, own shares of Outlook Therapeutics, Inc. (NASDAQ:OTLK)?
  • Did you purchase your shares between December 29, 2022 and August 29, 2023, inclusive?
  • Did you lose money in your investment in Outlook Therapeutics, Inc.?
  • Do you want to discuss your rights?

Bernstein Liebhard LLP announces that a securities class action lawsuit has been filed on behalf of investors who purchased or acquired the securities of Outlook Therapeutics, Inc. ("Outlook" or the "Company") (NASDAQ:OTLK) between December 29, 2022 and August 29, 2023, inclusive (the "Class Period"). The lawsuit was filed in the United States District Court for the District of New Jersey and alleges violations of the Securities Exchange Act of 1934 against the Company and certain of its officers (the "Complaint").

If you purchased or acquired Outlook securities, and/or would like to discuss your legal rights and options please visit Outlook Therapeutics, Inc. Shareholder Class Action Lawsuit or contact Peter Allocco at (212) 951-2030 or pallocco@bernlieb.com.

According to the Complaint, Outlook is a late clinical-stage biopharmaceutical company that focuses on developing and commercializing monoclonal antibodies for various ophthalmic ...

Full story available on Benzinga.com


Disclaimer: The views, recommendations, and opinions expressed in this content belong solely to the third-party experts. This site was not involved in the writing and production of this article.


Disclaimer Press Release Banner